Arrowhead Pharma stock holds steady as Cantor Fitzgerald reiterates Overweight rating

Investing.comWednesday, November 19, 2025 at 1:17:53 PM
Arrowhead Pharma stock holds steady as Cantor Fitzgerald reiterates Overweight rating
  • Arrowhead Pharma's stock holds steady as Cantor Fitzgerald reiterates its Overweight rating, indicating a positive outlook for the company.
  • This development is significant as it reflects investor confidence and may influence market perceptions, potentially leading to increased interest in Arrowhead Pharma's shares.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Cantor Fitzgerald lowers Meta stock price target to $720 on cloud costs
NegativeFinancial Markets
Cantor Fitzgerald has reduced its stock price target for Meta to $720, citing increased cloud costs as a significant factor. This adjustment reflects concerns about the company's financial outlook amidst rising operational expenses.